Investor Presentation Full Year 2021
97
Investor presentation Full year 2021
EMEA at a glance
EMEA
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
250
DKK
billion
31%
100
Full year 2021
Sales
(mDKK)
Growth²
80%
Total GLP-13
10,209
38%
200
28%
I
80
00
GLP-1
Long-acting insulin4
6,729
6%
30%¹
60%
Premix insulin5
2,879
3%
150
223
100
171
134
50
60
40
Fast-acting insulin
6,454
0%
60
Human insulin
3%1
Insulin
2,152
(8%)
40%
Total insulin
18,214
2%
40
Other Diabetes care?
713
1%
20
OAD 20%
Diabetes care
29,136
12%
20
10%1
Obesity care
1,809
66%
(SaxendaⓇ)
0
2019
0
0%
2030
2045
Nov
2016
Nov
2021
Diabetes & Obesity
30,945
14%
care
Population with diabetes
Diabetes growth rate
Biopharm³
6,761
3%
GLP-1 MS
-Insulin MS
-OAD MS
Total
37,706
12%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas 9th Edition 2019;
EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
Nov 2021: Novo Nordisk 48%, Sanofi 32% and Eli Lilly 16%; Competitor GLP-1
value market shares, as of Nov 2021: Novo Nordisk 58%, Eli Lilly 38% and
AstraZeneca 3%; OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT,
Nov 2021 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 5 Comprises RyzodegⓇ and
NovoMixⓇ: 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and
needles; 8 Comprises primarily NovoSevenⓇ, Novo Eight® NovoThirteenⓇ,
Refixia®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation